BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olvimulogene nanivacirepvec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olvimulogene nanivacirepvec\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07136285-2654@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olvimulogene nanivacirepvec: Phase 1/2 readout est. (NCT07136285)
DESCRIPTION:Olvimulogene nanivacirepvec\, phase 1/2.\nStudy: Olvi-Vec Combi
 ned With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07136285
URL:https://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05281471-2654@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Olvimulogene nanivacirepvec: Phase 3 readout est. (NCT05281471)
DESCRIPTION:Olvimulogene nanivacirepvec\, phase 3\, Ovarian Cancer.\nStudy:
  Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared
  to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resista
 nt/Refractory Ovarian Cancer (PRROC) (OnPrime\, GOG-3076)\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/olvimulogene-nanivacirepvec#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05281471
URL:https://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463665-2654@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Olvimulogene nanivacirepvec: Phase 2 readout est. (NCT06463665)
DESCRIPTION:Olvimulogene nanivacirepvec\, phase 2\, Non-Small Cell Lung Can
 cer.\nStudy: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-d
 oublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Doc
 etaxel in NSCL Cancer\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olvimulogene-nanivacirepvec
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 63665
URL:https://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
